EFC6596 (CINJ 070703): A Randomized, Open Label Multi-Center Study Of Single Agent Larotaxel (XRP9881) Compared To Continuous Administration of 5-FU For The Treatment Of Patients With Advanced Pancreatic Cancer Previously Treated With A Gemcitabine-Containing Regimen.
Phase of Trial: Phase III
Latest Information Update: 05 Jun 2016
At a glance
- Drugs Capecitabine; Fluorouracil; Larotaxel
- Indications Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms PAPRIKA
- 30 Jun 2010 Actual patient number added.
- 30 Jun 2010 Results were presented at the 12th World Congress on Gastrointestinal Cancer (2010).
- 29 Dec 2009 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History